Adam D. Cohen, MD, on Multiple Myeloma: Findings on CART-BCMA Infusions

Posted: Monday, December 11, 2017

Adam D. Cohen, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses data on the safety and efficacy of B-cell maturation antigen-specific chimeric antigen receptor T cells with cyclophosphamide conditioning for refractory multiple myeloma.